[go: up one dir, main page]

LTC2922872I2 - - Google Patents

Info

Publication number
LTC2922872I2
LTC2922872I2 LTPA2022507C LTPA2022507C LTC2922872I2 LT C2922872 I2 LTC2922872 I2 LT C2922872I2 LT PA2022507 C LTPA2022507 C LT PA2022507C LT PA2022507 C LTPA2022507 C LT PA2022507C LT C2922872 I2 LTC2922872 I2 LT C2922872I2
Authority
LT
Lithuania
Application number
LTPA2022507C
Other languages
Lithuanian (lt)
Original Assignee
Janssen Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2922872(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech, Inc. filed Critical Janssen Biotech, Inc.
Publication of LTPA2022507I1 publication Critical patent/LTPA2022507I1/lt
Publication of LTC2922872I2 publication Critical patent/LTC2922872I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LTPA2022507C 2012-11-21 2022-06-06 LTC2922872I2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261728912P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
US201361864717P 2013-08-12 2013-08-12
US201361892797P 2013-10-18 2013-10-18
PCT/US2013/071288 WO2014081954A1 (en) 2012-11-21 2013-11-21 BISPECIFIC EGFR/c-Met ANTIBODIES

Publications (2)

Publication Number Publication Date
LTPA2022507I1 LTPA2022507I1 (en) 2022-06-27
LTC2922872I2 true LTC2922872I2 (en) 2024-09-10

Family

ID=50728148

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP18199421.1T LT3447069T (en) 2012-11-21 2013-11-21 BIS-SPECIFIC EGFR / C-MET ANTIBODIES
LTEP13856592.4T LT2922872T (en) 2012-11-21 2013-11-21 Bispecific egfr/c-met antibodies
LTPA2022507C LTC2922872I2 (en) 2012-11-21 2022-06-06

Family Applications Before (2)

Application Number Title Priority Date Filing Date
LTEP18199421.1T LT3447069T (en) 2012-11-21 2013-11-21 BIS-SPECIFIC EGFR / C-MET ANTIBODIES
LTEP13856592.4T LT2922872T (en) 2012-11-21 2013-11-21 Bispecific egfr/c-met antibodies

Country Status (35)

Country Link
US (3) US9593164B2 (en)
EP (4) EP3808767B1 (en)
JP (5) JP6423357B2 (en)
KR (4) KR20220032654A (en)
CN (2) CN113201073A (en)
AU (4) AU2013347962B2 (en)
BR (1) BR112015011717B1 (en)
CA (2) CA2893505C (en)
CL (1) CL2015001356A1 (en)
CY (2) CY1121270T1 (en)
DK (2) DK2922872T3 (en)
EA (1) EA031184B1 (en)
ES (3) ES2700231T3 (en)
FI (1) FIC20220016I1 (en)
FR (1) FR22C1018I2 (en)
HR (2) HRP20182128T1 (en)
HU (3) HUE041499T2 (en)
IL (1) IL238796B (en)
LT (3) LT3447069T (en)
LU (1) LUC00257I2 (en)
MX (1) MX361088B (en)
NI (1) NI201500069A (en)
NL (1) NL301173I2 (en)
NO (1) NO2022012I1 (en)
NZ (1) NZ708352A (en)
PE (1) PE20151181A1 (en)
PH (1) PH12015501118A1 (en)
PL (1) PL2922872T3 (en)
PT (2) PT3447069T (en)
RS (2) RS58192B1 (en)
SG (1) SG11201503938VA (en)
SI (2) SI3447069T1 (en)
SM (2) SMT201800624T1 (en)
UA (1) UA117121C2 (en)
WO (1) WO2014081954A1 (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101802015B (en) 2007-03-29 2015-05-06 根马布股份公司 Bispecific antibody and its production method
ES2751549T3 (en) * 2009-11-30 2020-04-01 Janssen Biotech Inc Fc antibody mutants with ablated effector functions
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
DK2560993T3 (en) 2010-04-20 2024-10-14 Genmab As HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
CN107253992B (en) 2010-05-27 2022-03-11 根马布股份公司 Monoclonal antibody against HER2
AU2012328322A1 (en) 2011-10-27 2014-06-12 Genmab A/S Production of heterodimeric proteins
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN113201073A (en) * 2012-11-21 2021-08-03 詹森生物科技公司 Bispecific EGFR/c-Met antibodies
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
WO2015057545A2 (en) 2013-10-14 2015-04-23 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
BR112016017897A8 (en) * 2014-02-04 2020-06-30 Astellas Pharma Inc use of heterocyclic diamino carboxamide compound in the treatment of axl-related cancer, pharmaceutical composition and combination
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
KR102309881B1 (en) 2014-11-21 2021-10-06 삼성전자주식회사 Pharmaceutical composition for combination therapy containing dual inhibitor of c-Met and EGFR and IGF-1R inhibitor
JP6769962B2 (en) * 2014-12-03 2020-10-14 オークランド ユニサービシーズ リミティド Kinase inhibitor prodrugs for cancer treatment
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
WO2016097300A1 (en) 2014-12-19 2016-06-23 Genmab A/S Rodent bispecific heterodimeric proteins
DK3237005T3 (en) * 2014-12-22 2024-11-18 Systimmune Inc Bispecific tetravalent antibodies and methods of making and using thereof
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016182513A1 (en) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Profiling of hepatocellular carcinoma and applications thereof
RS61800B1 (en) 2015-10-23 2021-06-30 Merus Nv Binding molecules that inhibit cancer growth
WO2017076492A1 (en) * 2015-11-03 2017-05-11 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
MA43186B1 (en) 2015-11-03 2022-03-31 Janssen Biotech Inc Antibodies specifically binding to pd-1 and uses thereof
TWI738713B (en) * 2016-02-06 2021-09-11 開曼群島商岸邁生物科技有限公司 Fabs-in-tandem immunoglobulin and uses thereof
RU2751341C2 (en) 2016-05-26 2021-07-13 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Egfr inhibitor compounds
KR101985299B1 (en) * 2016-06-03 2019-09-03 삼성전자주식회사 Anti-c-Met/anti-Nrp1 bispecific antibody
MX2018016185A (en) * 2016-06-21 2019-03-28 Janssen Biotech Inc Cysteine engineered fibronectin type iii domain binding molecules.
WO2018042385A2 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
TWI782930B (en) 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
CN110177571B (en) 2016-11-18 2024-05-24 加利福尼亚大学董事会 Engineered antibodies and their uses
BR112019012154A2 (en) 2016-12-14 2019-11-12 Janssen Biotech Inc cd8a-binding fibronectin type iii domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
WO2018145048A1 (en) * 2017-02-06 2018-08-09 Academia Sinica Recombinant proteins and uses thereof
EA201992063A1 (en) 2017-03-31 2020-03-26 Мерус Н.В. BINDING ErbB-2 AND ErbB-3 SPECIFIC ANTIBODIES FOR USE FOR TREATMENT OF CELLS THAT CONTAIN THE NRG-1 FUSED GENE
WO2018212656A1 (en) 2017-05-17 2018-11-22 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
KR102078292B1 (en) * 2017-05-30 2020-02-19 주식회사 종근당 A novel anti c-Met antibody and use thereof
HUE071182T2 (en) * 2017-08-09 2025-08-28 Merus Nv EGFR and CMET binding antibodies
US11078263B2 (en) * 2017-08-25 2021-08-03 Janssen Biotech, Inc. Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them
WO2019114793A1 (en) * 2017-12-13 2019-06-20 凯惠科技发展(上海)有限公司 Egfr antibody, preparation method therefor and application thereof
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MA52777A (en) 2018-05-24 2021-04-14 Janssen Biotech Inc PSMA LIAISON OFFICERS AND CORRESPONDING USES
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
WO2020055761A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
MX2021002805A (en) 2018-09-10 2021-07-15 Mirati Therapeutics Inc Combination therapies.
JP7539902B2 (en) 2018-10-22 2024-08-26 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Glucagon-like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion protein and uses thereof
MX2021002804A (en) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Combination therapies.
TWI874341B (en) 2018-12-18 2025-03-01 美商健生生物科技公司 Methods of producing heterodimeric antibodies
AU2020229467A1 (en) * 2019-02-26 2021-08-12 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-EGFR/c-met antibodies
MA55717A (en) 2019-04-19 2022-02-23 Janssen Biotech Inc METHODS OF TREATMENT OF PROSTATE CANCER WITH ANTI-PSMA/CD3 ANTIBODY
EP3968985A4 (en) * 2019-05-14 2023-07-26 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
JOP20210304A1 (en) * 2019-05-14 2023-01-30 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
KR20220063185A (en) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 Radiolabeled MET binding protein for immuno-PET imaging
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company CD71-BINDING FIBRONECTIN TYPE III DOMAINS
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
JOP20220184A1 (en) * 2020-02-12 2023-01-30 Janssen Biotech Inc TREATMENT OF PATIENTS HAVING c-MET EXON 14 SKIPPING MUTATIONS
TW202207940A (en) 2020-04-14 2022-03-01 美商健生生物科技公司 Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
KR20230053686A (en) * 2020-08-25 2023-04-21 얀센 바이오테크 인코포레이티드 Treatment of non-small cell lung cancer with EGFR mutations
AR123340A1 (en) * 2020-08-26 2022-11-23 Janssen Biotech Inc STABLE FORMULATIONS COMPRISING A BISECFIC ANTIBODY TO EGFR/c-MET
CN116669763A (en) 2020-09-14 2023-08-29 詹森药业有限公司 FGFR inhibitor combination therapy
PE20240761A1 (en) 2021-01-28 2024-04-17 Janssen Biotech Inc PSMA BINDING PROTEINS AND USES OF THESE
JP2024509920A (en) 2021-03-09 2024-03-05 ヤンセン バイオテツク，インコーポレーテツド Treatment of cancers lacking EGFR activating mutations
MX2023012124A (en) 2021-04-14 2024-01-11 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof.
EP4323409A4 (en) 2021-04-14 2025-04-16 ARO Biotherapeutics Company Cd71 binding fibronectin type iii domains
TW202308689A (en) * 2021-04-21 2023-03-01 美商健生生物科技公司 High concentration bispecific antibody formulations
TW202309094A (en) * 2021-05-18 2023-03-01 美商健生生物科技公司 Methods for identifying cancer patients for combination treatment
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
US20250230248A1 (en) * 2021-10-18 2025-07-17 Tavotek Biotherapeutics (Hong Kong) Limited Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
CN118742325A (en) 2022-01-28 2024-10-01 上海岸阔医药科技有限公司 Methods for preventing or treating diseases or conditions associated with anti-tumor agents
TW202342057A (en) 2022-02-07 2023-11-01 美商健生生物科技公司 Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2023155905A1 (en) 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 Compound and use thereof
CN114740108B (en) * 2022-03-28 2023-07-14 天津键凯科技有限公司 Method for measuring modification degree of polymer modified antibody drug
WO2024002256A1 (en) * 2022-06-29 2024-01-04 Doma Biopharmaceutical (Suzhou) Co., Ltd. Anti-egfr/met antibodies and uses thereof
JP2025522814A (en) * 2022-06-30 2025-07-17 ヤンセン バイオテツク，インコーポレーテツド Use of anti-EGFR/anti-MET antibodies to treat gastric or esophageal cancer
EP4624493A1 (en) * 2022-11-24 2025-10-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr
WO2024189544A1 (en) 2023-03-13 2024-09-19 Janssen Biotech, Inc. Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
WO2024193449A1 (en) * 2023-03-17 2024-09-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-her3 and anti-met antibodies and uses thereof
EP4454706A1 (en) * 2023-04-24 2024-10-30 Universität Stuttgart Novel egfr binding proteins
AR132710A1 (en) 2023-05-19 2025-07-23 Servier Lab ANTI-MET ANTIBODIES, ADCs, THEIR COMPOSITIONS AND USES
WO2024241273A1 (en) 2023-05-23 2024-11-28 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
TW202506733A (en) 2023-06-12 2025-02-16 美商安進公司 Lymphotoxin beta receptor agonist binding proteins
WO2025011471A1 (en) * 2023-07-07 2025-01-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Egfr/c-met bispecific binding protein and use thereof
WO2025017409A1 (en) 2023-07-14 2025-01-23 Janssen Biotech, Inc. Dosing regimen for therapies comprising bispecific antiegfr/c-met antibodies
WO2025025434A1 (en) * 2023-08-02 2025-02-06 百泰生物药业有限公司 Egfr/c-met bispecific antibody and use thereof
WO2025052273A1 (en) 2023-09-05 2025-03-13 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
CN119700964A (en) * 2023-09-28 2025-03-28 上海翰森生物医药科技有限公司 Use of bispecific antibody in preparation of medicine for treating cancer
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
TW202527997A (en) * 2023-11-15 2025-07-16 大陸商四川科倫博泰生物醫藥股份有限公司 Antibody-drug conjugates targeting egfr/c-met and preparation methods and uses thereof
WO2025131053A1 (en) * 2023-12-22 2025-06-26 Fortvita Biologics Inc. Bispecific antibody-drug conjugates targeting b7h3 and egfr and the use thereof
WO2025153988A1 (en) 2024-01-16 2025-07-24 Janssen Biotech, Inc. Use of amivantamab to treat colorectal cancer
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
ATE87659T1 (en) 1986-09-02 1993-04-15 Enzon Lab Inc BINDING MOLECULES WITH SINGLE POLYPEPTIDE CHAIN.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69025946T2 (en) 1989-09-08 1996-10-17 Univ Duke MODIFICATIONS OF THE STRUCTURE OF THE EGF RECEPTOR GENE IN HUMAN GLIOMA
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP1362868A3 (en) 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
PT1696031E (en) 1991-12-02 2010-06-25 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
DK0672142T3 (en) 1992-12-04 2001-06-18 Medical Res Council Multivalent and multi-specific binding proteins as well as their preparation and use
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP2380906A2 (en) 1997-06-12 2011-10-26 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
WO2002092771A2 (en) 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2002100348A2 (en) 2001-06-13 2002-12-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (en) 2001-09-26 2010-12-22 アイシン精機株式会社 Automotive door
US7842476B2 (en) 2002-09-06 2010-11-30 Isogenica Limited In vitro peptide expression library
BRPI0407446A (en) 2003-02-13 2006-01-31 Pharmacia Corp C-met Antibodies for cancer treatment
BRPI0412885A (en) * 2003-07-18 2006-10-03 Amgen Inc polypeptides, specific binding agents, nucleic acid molecules and isolated cell lines, host cells, compositions and antigen binding domain or antibody and methods of treating cancer and solid tumor in a patient, detecting growth factor level hepatocyte (hgf) in a sample, obtaining antibody and inhibiting hgf binding to met and decreasing or preventing the binding of any of the hepatocyte growth factor (hgf) -specific binding agents
HN2004000285A (en) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTIBODIES DIRECTED TO c-MET
US7932026B2 (en) 2004-06-04 2011-04-26 Genentech, Inc. EGFR mutations
CA2575402A1 (en) 2004-08-05 2006-02-09 Genentech, Inc. Humanized anti-cmet antagonists
MX2007002856A (en) 2004-09-02 2007-09-25 Genentech Inc Heteromultimeric molecules.
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DE102005028778A1 (en) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Multi-layer foil, useful for lining a flexible container, comprises a barrier layer, a stretch-poor plastic layer, an antistatic plastic layer and a layer containing a safe material for food
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
EP2231870A4 (en) 2007-12-19 2011-01-26 Centocor Ortho Biotech Inc Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
ES2564523T3 (en) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Design and generation of phage de novo human presentation libraries by fusion with pIX or pVII, vectors, antibodies and methods
RU2601892C2 (en) 2008-03-06 2016-11-10 Дженентек, Инк. Combined c-met and egfr antagonists therapy
TW201002346A (en) 2008-04-11 2010-01-16 Galaxy Biotech Llc Combination of HGF inhibitor and EGF inhibitor to treat cancer
CN102224255A (en) * 2008-08-15 2011-10-19 梅里麦克制药股份有限公司 Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
EP2349328A1 (en) 2008-10-01 2011-08-03 Ludwig Institute For Cancer Research Methods for the treatment of cancer
EP3128048B1 (en) 2008-10-31 2018-11-28 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CA2757669A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-1/anti-c-met antibodies
ES2708124T3 (en) 2009-04-27 2019-04-08 Oncomed Pharm Inc Procedure for preparing heteromultimeric molecules
AU2010289527C1 (en) * 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
ES2751549T3 (en) 2009-11-30 2020-04-01 Janssen Biotech Inc Fc antibody mutants with ablated effector functions
US9068011B2 (en) * 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
DK2560993T3 (en) * 2010-04-20 2024-10-14 Genmab As HETERODIMERIC ANTIBODY FC-CONTAINING PROTEINS AND METHODS FOR PRODUCTION THEREOF
EP3569256B1 (en) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
WO2011158061A1 (en) * 2010-06-15 2011-12-22 Alberto Bardelli Mlk4 gene, a new diagnostic and prognostic marker in cancers
EP2621953B1 (en) * 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
CN108341868B (en) 2010-11-05 2022-06-07 酵活有限公司 Antibody design for stable heterodimerization with mutations in the Fc domain
IL296507A (en) * 2011-10-10 2022-11-01 Hope City Meditops and Meditop binding antibodies and their use
KR102052774B1 (en) 2011-11-04 2019-12-04 자임워크스 인코포레이티드 Stable heterodimeric antibody design with mutations in the fc domain
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CN113201073A (en) * 2012-11-21 2021-08-03 詹森生物科技公司 Bispecific EGFR/c-Met antibodies

Also Published As

Publication number Publication date
AU2013347962A1 (en) 2015-05-28
CN104955838B (en) 2021-02-02
MX2015006387A (en) 2015-12-03
FIC20220016I1 (en) 2022-05-31
FR22C1018I2 (en) 2023-05-05
AU2021202394A1 (en) 2021-05-20
PH12015501118B1 (en) 2016-02-01
KR102373193B1 (en) 2022-03-10
AU2021202394B2 (en) 2024-03-07
LT3447069T (en) 2020-12-10
US20140141000A1 (en) 2014-05-22
PE20151181A1 (en) 2015-08-19
LTPA2022507I1 (en) 2022-06-27
US20140255408A1 (en) 2014-09-11
KR20250054125A (en) 2025-04-22
BR112015011717A2 (en) 2017-08-15
CA2893505C (en) 2023-02-21
UA117121C2 (en) 2018-06-25
HUE052548T2 (en) 2021-05-28
LT2922872T (en) 2018-12-27
RS58192B1 (en) 2019-03-29
CA2893505A1 (en) 2014-05-30
ES2700231T3 (en) 2019-02-14
CY1123550T1 (en) 2022-03-24
EP4420727A3 (en) 2024-10-23
JP7397105B2 (en) 2023-12-12
AU2019200441B2 (en) 2021-01-28
EP3447069A1 (en) 2019-02-27
NL301173I2 (en) 2022-06-15
JP6773746B2 (en) 2020-10-21
JP6423357B2 (en) 2018-11-14
EP2922872A4 (en) 2016-07-06
HUE041499T2 (en) 2019-05-28
BR112015011717B1 (en) 2023-12-12
US9580508B2 (en) 2017-02-28
ES2971536T3 (en) 2024-06-05
JP2016505537A (en) 2016-02-25
IL238796B (en) 2019-06-30
EP3808767A1 (en) 2021-04-21
SMT201800624T1 (en) 2019-01-11
PL2922872T3 (en) 2019-03-29
SI3447069T1 (en) 2021-02-26
CY1121270T1 (en) 2020-05-29
DK3447069T3 (en) 2020-11-16
SI2922872T1 (en) 2019-01-31
ES2831374T3 (en) 2021-06-08
PT3447069T (en) 2020-11-13
AU2019200441A1 (en) 2019-02-07
EP4420727A2 (en) 2024-08-28
US9695242B2 (en) 2017-07-04
AU2013347962B2 (en) 2018-10-25
CA3182876A1 (en) 2014-05-30
AU2024203417A1 (en) 2024-06-13
NI201500069A (en) 2015-10-19
HRP20201848T1 (en) 2021-01-08
EP2922872B1 (en) 2018-10-10
EP3447069B1 (en) 2020-09-23
LUC00257I2 (en) 2025-04-25
JP2021006561A (en) 2021-01-21
CN113201073A (en) 2021-08-03
SMT202000619T1 (en) 2021-01-05
CN104955838A (en) 2015-09-30
EP3808767C0 (en) 2023-12-06
EP3808767B1 (en) 2023-12-06
JP7019771B2 (en) 2022-02-15
KR20240005211A (en) 2024-01-11
US20170101475A1 (en) 2017-04-13
WO2014081954A1 (en) 2014-05-30
NL301173I1 (en) 2022-05-04
JP2019048817A (en) 2019-03-28
MX361088B (en) 2018-11-26
SG11201503938VA (en) 2015-06-29
CL2015001356A1 (en) 2015-11-06
JP2024026236A (en) 2024-02-28
HUS2200016I1 (en) 2022-05-28
EA031184B1 (en) 2018-11-30
IL238796A0 (en) 2015-06-30
US9593164B2 (en) 2017-03-14
EA201590985A1 (en) 2015-11-30
JP2022062155A (en) 2022-04-19
KR102795571B1 (en) 2025-04-11
DK2922872T3 (en) 2019-01-02
PT2922872T (en) 2019-01-18
KR20220032654A (en) 2022-03-15
FR22C1018I1 (en) 2022-06-17
KR20150087365A (en) 2015-07-29
HRP20182128T1 (en) 2019-02-08
RS61057B1 (en) 2020-12-31
PH12015501118A1 (en) 2016-02-01
NO2022012I1 (en) 2022-05-06
NZ708352A (en) 2019-10-25
EP2922872A1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
LTPA2022507I1 (en)
BR112014017635A2 (en)
BR112014017614A2 (en)
BR112014017625A2 (en)
BR112014017659A2 (en)
BR112014018371A2 (en)
BR112014018165A2 (en)
BR112014017646A2 (en)
BR112014017638A2 (en)
BR112014017607A2 (en)
BR112014017609A2 (en)
BR112015010799A2 (en)
BR112014017634A2 (en)
BR112014017644A2 (en)
BR112014017618A2 (en)
BR112014017647A2 (en)
BR112014019427A2 (en)
BR112014017623A2 (en)
BR112014019559A2 (en)
BR112014017630A2 (en)
BR112014017652A2 (en)
BR112014017631A2 (en)
BR112014017627A2 (en)
BR112014017641A2 (en)
BR112014017621A2 (en)